BETAPAR Drug Patent Profile
✉ Email this page to a colleague
When do Betapar patents expire, and what generic alternatives are available?
Betapar is a drug marketed by Schering and is included in one NDA.
The generic ingredient in BETAPAR is meprednisone. Additional details are available on the meprednisone profile page.
Summary for BETAPAR
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 71 |
Patent Applications: | 5,480 |
DailyMed Link: | BETAPAR at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for BETAPAR
US Patents and Regulatory Information for BETAPAR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Schering | BETAPAR | meprednisone | TABLET;ORAL | 016053-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |